Big effect
In a 12-week trial, a Bifidobacterium infantis strain slashed respiratory infection incidence to 15% versus 42% in preschoolers — but the effect comes from a single, early study.
This large effect size is eye-catching, but because it's one of the first trials on this specific pairing, the result needs replication before we can trust it broadly — especially in adults or other age groups.
Healthy preschool children who took Bifidobacterium infantis YLGB-1496 for 12 weeks had far fewer respiratory infections (15% vs. 42% in the placebo group). The probiotic also reduced diarrhea and improved gut microbiome stability, tilting immune markers toward an anti-inflammatory state. However, this is an early finding, and the dose wasn't specified, so treat the result as promising but not definitive.
Where this fits in the evidence
This is among the first studies we've indexed on Bifidobacterium infantis for Reduced Respiratory Infections — treat it as an early signal until more research accumulates.
The study
- Clinical Trial
- 2026-01-05
- Frontiers in nutrition
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.